500, 750 and 1000 mg daily. [46] A total of 18 out of 33 patients (55%) experienced a decline in PSA of more than 50%, resulting in a recommended Phase II abiraterone acetate dose of 1000 mg.
Abiraterone acetate is currently given for two indications: Newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with prednisone 5 mg daily. For metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback